I am a Professor and Deputy Dean of Research & Innovation at the Faculty of Engineering, Universiti Malaya. I am a registered Professional Engineer (PEng) with the Board of Engineers Malaysia and an ASEAN Chartered Professional Engineer (ACPE). I previously served as the President of the Malaysian Thermoelectric Society and held administrative positions including Head of the Department of Mechanical Engineering (2016-2019). I also serve as a program examiner for the Engineering Accreditation Council (EAC), Malaysia, contributing to the quality assurance of engineering education in the country. My research focuses on energy materials, electronics packaging (solder alloys) and MEMS. I have published over 200 ISI-indexed journal articles, 2 books, and 10 book chapters. My work has garnered over 5,200 citations with an h-index of 37. I hold 7 patents related to my research areas. I have been invited to deliver 8 keynote talks at international conferences and 15 invited talks at local and international conferences. I have secured research grants totaling RM13.7 million and led projects worth RM1.7 million. I have served as an examiner for 31 PhD theses (17 international) and 26 Master's theses (1 international). My expertise is also recognized through my appointment as a reviewer for more than 35 journals and my role as an evaluator for national and international research funding applications. I have supervised more than 35 postgraduate students (specifically 21 PhD, 18 Master's completed, and 9 ongoing). 

Prof. Ali Mohammad Sharifi is a scholar with over 27 years of experience in Molecular Pharmacology at the Iran University of Medical Sciences and currently joined as a professor of regenerative Medicine in the Tissue Engineering Group at NOCERAL, department of Orthopedics Surgery, School of Medicine. He obtained his Ph.D. from the University of Glasgow in 1992 and in 2018, he further enriched his expertise by acquiring a Tissue Banking Diploma from the National University of Singapore. Throughout his career, Prof. Sharifi has undertaken international research, including working at McGill University in Canada and at Max Plank Institute in Germany. His research output includes over 100 publications in high-impact journals, along with several patented innovations. He has held various administrative and editorial roles in academia, and has served as a peer reviewer for numerous high-impact journals. His dedication to education is evident through his mentorship of undergraduate and postgraduate students, particularly Ph.D. candidates specializing in molecular medicine, tissue engineering, molecular pharmacology, and cell therapy.  Prof. Sharifi's research expertise involves the fields of cell therapy and regenerative Pharmacology, with a particular emphasis on translational medicine. His extensive body of work includes pioneering studies on pharmacological priming, therapeutic angiogenesis, and innovative strategies to enhance the effectiveness of stem cell therapy by manipulating HIF-1α stabilization, especially in the context of diabetes. Additionally, his research activities include bone and cartilage regeneration, employing a diverse array of strategies such as stem cells and biologically derived products like amniotic membrane extract and mesenchymal stem cell-derived secretome. He has also explored the potential of herbal agents in regenerative medicine.  His contributions extend to the development of custom-made bio-implants for addressing large bone defects and the design and production of various wound dressings, with a specific focus on diabetic wound healing. In recent times, Prof. Sharifi has harnessed the transformative power of CRISPR gene editing technology to combat synovial fibrosis induced by osteoarthritis. In summary, Professor Sharifi is an active scientist in the field of Molecular Pharmacology and Regenerative Medicine, exemplifying innovation, and dedication to advancing scientific knowledge for improvement of healthcare and human well-being.  

Dr. Nur Kusaira is a dedicated plant biotechnology researcher with a deep passion for unlocking the therapeutic and nutritional potential of plant natural products. Her academic journey began with a Bachelor's degree in Plant Resource Science and Management from Universiti Malaysia Sarawak (UNIMAS) in 2008, majoring in Plant Systematics. She was awarded the Best Undergraduate Thesis that year. She went on to earn a Master's in Healthcare Biotechnology from Universiti Sains Malaysia (USM), where she focused on in silico screening of phytocompounds against H5N1 and H1N1 influenza viruses under the supervision of Prof. Dr. Habibah Abd Wahab. In 2012, she undertook a research attachment at UC San Diego, where she conducted molecular dynamics simulations of plant-based inhibitors targeting the NS2B/NS3 protein of Dengue virus type 2 (DENV-2). Her career then led her to Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm), where she managed the USM-RIKEN natural product discovery grant, working on the development of a comprehensive library of Malaysian plant extracts intended for diverse bioactivity screenings, laying the groundwork for systematic exploration of Malaysia’s phytochemical biodiversity. Though initially set to pursue her PhD at USM, Dr. Nur Kusaira was awarded an international PhD scholarship by Universiti Malaya and joined the University of Copenhagen, Denmark, under Prof. Dr Henrik Toft Simonsen. Her PhD work made headlines in plant synthetic biology, she pioneered the use of Physcomitrella patens for stable in vivo assembly of biosynthetic gene clusters, achieving the first stable plant-based production of artemisinin, a vital antimalarial drug, marking a breakthrough in sustainable pharmaceutical production. Her research continues at the intersection of plant science, biotechnology, and health. She focuses on: Functional Food Innovation: Developing plant-based bioactives with nutraceutical properties for preventive health and wellness. Drug Discovery: Leveraging computational tools to identify potent, selective plant-based inhibitors targeting cancer, viral and microbial proteins. Plant Synthetic Biology: Exploring plant platforms like moss and medicinal species for scalable biosynthesis of valuable therapeutic molecules. Dr. Nur Kusaira’s work reflects a commitment to sustainability, global health, and innovation paving the way for plant-derived therapeutics that are effective, affordable, and accessible worldwide.